Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study

Journal:
PLOS Medicine
Published:
DOI:
10.1371/journal.pmed.1004499
Affiliations:
3
Authors:
9
Go to article
Institutions Authors Share
Daiichi Sankyo, Japan
8.000000
 0.89
Kawasaki Medical University, Japan
1.000000
 0.11
Interested in Immunology?